- Home
- ABAT vs ADAG Comparison
ABAT vs ADAG Comparison
Compare ABAT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- ADAG
- Stock Information
- Founded
- ABAT 2011
- ADAG 2011
- Country
- ABAT United States
- ADAG China
- Employees
- ABAT N/A
- ADAG N/A
- Industry
- ABAT Metal Mining
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ABAT Basic Materials
- ADAG Health Care
- Exchange
- ABAT Nasdaq
- ADAG Nasdaq
- Market Cap
- ABAT 71.7M
- ADAG 85.9M
- IPO Year
- ABAT N/A
- ADAG 2021
- Fundamental
- Price
- ABAT $2.00
- ADAG $1.84
- Analyst Decision
- ABAT
- ADAG Strong Buy
- Analyst Count
- ABAT 0
- ADAG 1
- Target Price
- ABAT N/A
- ADAG $5.00
- AVG Volume (30 Days)
- ABAT 14.0M
- ADAG 24.0K
- Earning Date
- ABAT 02-16-2025
- ADAG 03-09-2025
- Dividend Yield
- ABAT N/A
- ADAG N/A
- EPS Growth
- ABAT N/A
- ADAG N/A
- EPS
- ABAT N/A
- ADAG N/A
- Revenue
- ABAT $545,460.00
- ADAG $815,746.00
- Revenue This Year
- ABAT $31,748.62
- ADAG N/A
- Revenue Next Year
- ABAT N/A
- ADAG $2.70
- P/E Ratio
- ABAT N/A
- ADAG N/A
- Revenue Growth
- ABAT N/A
- ADAG N/A
- 52 Week Low
- ABAT $0.73
- ADAG $1.74
- 52 Week High
- ABAT $4.11
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- ABAT 53.28
- ADAG 40.33
- Support Level
- ABAT $1.72
- ADAG $1.76
- Resistance Level
- ABAT $2.25
- ADAG $2.07
- Average True Range (ATR)
- ABAT 0.50
- ADAG 0.14
- MACD
- ABAT -0.09
- ADAG -0.00
- Stochastic Oscillator
- ABAT 11.72
- ADAG 23.53
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.